rasagiline has been researched along with Nerve Degeneration in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biton, IE; Dror, V; Eliash, S; Rehavi, M | 1 |
| Schapira, AH | 1 |
| Cohen, S; Dror, V; Eliash, S; Rehavi, M | 1 |
| Klivényi, P; Rákóczi, K; Vécsei, L | 1 |
| Eilam, R; Eliash, S; Shteter, N | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Amit, T; Mandel, S; Sagi, Y; Youdim, MB | 1 |
| Blaugrund, E; Cohen, S; Fine, T; Litinetsky, L; Mayk, A; Nyska, A; Speiser, Z | 1 |
| Akao, Y; Maruyama, W; Naoi, M; Yamaoka, Y; Yi, H | 1 |
| Jankovic, J; Le, W; Li, J; Pan, T; Xie, W; Youdim, MB; Zhu, W | 1 |
3 review(s) available for rasagiline and Nerve Degeneration
| Article | Year |
|---|---|
Rasagiline in neurodegeneration.
Topics: Animals; Humans; Indans; Nerve Degeneration; Neuroprotective Agents | 2008 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone | 2009 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
7 other study(ies) available for rasagiline and Nerve Degeneration
| Article | Year |
|---|---|
Rasagiline prevents neurodegeneration in thiamine deficient rats-a longitudinal MRI study.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Disease Progression; Indans; Kaplan-Meier Estimate; Lateral Ventricles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroprotective Agents; Organ Size; Pyrithiamine; Rats; Rats, Sprague-Dawley; Thalamus; Thiamine Deficiency | 2014 |
Neuroprotection by rasagiline in thiamine deficient rats.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Indans; Kaplan-Meier Estimate; Male; Maze Learning; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroprotective Agents; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Thiamine Deficiency | 2009 |
Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Indans; Male; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Paraventricular Hypothalamic Nucleus; Rats; Rats, Inbred SHR; Rats, Wistar; Third Ventricle; Treatment Outcome; Vasopressins | 2005 |
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Cell Survival; Cells, Cultured; DNA, Complementary; Dopamine; Dopamine Agents; Enzyme Activation; Gene Expression Regulation; Immunohistochemistry; Indans; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Receptor Protein-Tyrosine Kinases; Signal Transduction; Substantia Nigra | 2007 |
Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.
Topics: Animals; Brain Infarction; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Indans; Infarction, Middle Cerebral Artery; Male; Maze Learning; Nerve Degeneration; Neuroprotective Agents; Rats; Rats, Wistar; Recovery of Function; Time Factors; Treatment Outcome | 2007 |
Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
Topics: Cell Death; Cell Line, Tumor; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation; Humans; Indans; Mitochondria; Mitochondrial Membranes; Monoamine Oxidase; Nerve Degeneration; Neuroblastoma; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Salsoline Alkaloids; Serotonin; Signal Transduction; Tetrahydroisoquinolines; Transfection | 2006 |
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.
Topics: Acetylcysteine; Animals; Dopamine; Indans; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Selegiline | 2008 |